Skip to main content
Atrás
UCBJY logo

UCB S.A.

Calidad de datos: 100%
UCBJY
OTC Healthcare Biotechnology
$144.63
▲ $3.01 (2.13%)
Cap. Mercado: 55.06B
También listada como UCBJF OTC
Rango del Día
$143.81 $145.91
Rango de 52 Semanas
$71.16 $168.76
Volumen
3,348
Promedio 50D / 200D
$152.79 / $129.82
Cierre Anterior
$141.62

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 36.8 0.4
P/B 5.1 2.9
ROE % 14.3 3.7
Net Margin % 20.1 3.9
Rev Growth 5Y % 6.5 10.0
D/E 0.2 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $11.65
$11.29 – $11.93
 13 B 1
FY2029 $10.16
$9.85 – $10.40
 12 B 1
FY2028 $8.57
$8.31 – $8.77
 11 B 1

Puntos Clave

Revenue grew 6.51% annually over 5 years — modest growth
Earnings grew 40.52% over the past year
ROE of 14.33% — decent returns on equity
Net margin of 20.13% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 1.81B in free cash flow

Crecimiento

Revenue Growth (5Y)
6.51%
Revenue (1Y)20.86%
Earnings (1Y)40.52%
FCF Growth (3Y)101.55%

Calidad

Return on Equity
14.33%
ROIC6.41%
Net Margin20.13%
Op. Margin15.06%

Seguridad

Debt / Equity
0.21
Current Ratio1.38
Interest Coverage9.11

Valoración

P/E Ratio
36.79
P/B Ratio5.07
EV/EBITDA49.16
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20.86% Revenue Growth (3Y) 18.99%
Earnings Growth (1Y) 40.52% Earnings Growth (3Y) 108.88%
Revenue Growth (5Y) 6.51% Earnings Growth (5Y) 9.06%
Profitability
Revenue (TTM) 7.44B Net Income (TTM) 1.50B
ROE 14.33% ROA 8.25%
Gross Margin 71.14% Operating Margin 15.06%
Net Margin 20.13% Free Cash Flow (TTM) 1.81B
ROIC 6.41% FCF Growth (3Y) 101.55%
Safety
Debt / Equity 0.21 Current Ratio 1.38
Interest Coverage 9.11 Dividend Yield 0.01%
Valuation
P/E Ratio 36.79 P/B Ratio 5.07
P/S Ratio 7.41 PEG Ratio 0.76
EV/EBITDA 49.16 Dividend Yield 0.01%
Market Cap 55.06B Enterprise Value 55.06B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.44B 6.15B 5.25B 5.52B 5.78B
Net Income 1.50B 1.07B 343.00M 418.00M 1.06B
EPS (Diluted) 3.86 2.74 0.88 1.08 2.73
Gross Profit 5.29B 4.40B 3.55B 3.84B 4.34B
Operating Income 1.12B 1.32B 604.00M 585.00M 1.28B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18.15B 17.35B 15.54B 15.87B 14.21B
Total Liabilities 7.29B 7.32B 6.56B 6.80B 5.82B
Shareholders' Equity 10.86B 10.03B 8.98B 9.06B 8.39B
Total Debt 2.24B 3.03B 3.04B 2.90B 2.12B
Cash & Equivalents 2.25B 1.57B 861.00M 899.00M 1.26B
Current Assets 6.05B 4.79B 3.44B 3.30B 3.71B
Current Liabilities 4.40B 3.53B 2.62B 3.11B 2.82B

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#851 of 1024
28

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026